420 related articles for article (PubMed ID: 25447947)
41. Cystic fibrosis liver disease in the new era of cystic fibrosis transmembrane conductance regulator (CFTR) modulators.
Eldredge JA; Oliver MR; Ooi CY
Paediatr Respir Rev; 2024 Jun; 50():54-61. PubMed ID: 38281822
[TBL] [Abstract][Full Text] [Related]
42. Cystic fibrosis transmembrane conductance regulator biomarkers in 'real life': can we evaluate individual efficacy of cystic fibrosis transmembrane conductance regulator therapy?
van Koningsbruggen-Rietschel S; Naehrlich L
Ther Adv Respir Dis; 2015 Aug; 9(4):198-200. PubMed ID: 26175480
[No Abstract] [Full Text] [Related]
43. Potentiators for cystic fibrosis - targeting the underlying molecular defect.
Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
Paediatr Respir Rev; 2015 Jun; 16(3):162-4. PubMed ID: 26002404
[No Abstract] [Full Text] [Related]
44. [Cystic fibrosis: new treatments targeting the CFTR protein].
Fajac I; Sermet-Gaudelus I
Rev Mal Respir; 2013 Apr; 30(4):255-61. PubMed ID: 23664284
[TBL] [Abstract][Full Text] [Related]
45. Promising new era dawns for cystic fibrosis treatment.
Corbyn Z
Lancet; 2012 Apr; 379(9825):1475-6. PubMed ID: 22530244
[No Abstract] [Full Text] [Related]
46. Cystic fibrosis drug is not cost effective, says NICE.
Gulland A
BMJ; 2016 Jun; 353():i3409. PubMed ID: 27325384
[No Abstract] [Full Text] [Related]
47. Exhaled nitric oxide in stable adult cystic fibrosis patients, during exacerbation and following CFTR-modifying treatment.
Vincken S; Verbanck S; De Wachter E; Vanderhelst E
Eur Respir J; 2019 May; 53(5):. PubMed ID: 30819814
[No Abstract] [Full Text] [Related]
48. Theratyping in cystic fibrosis.
Crawford KJ; Downey DG
Curr Opin Pulm Med; 2018 Nov; 24(6):612-617. PubMed ID: 30124524
[TBL] [Abstract][Full Text] [Related]
49. [FUTURE THERAPIES FOR CYSTIC FIBROSIS].
Fajac I
Rev Prat; 2015 Oct; 65(8):1106-8. PubMed ID: 26749719
[TBL] [Abstract][Full Text] [Related]
50. [Combined administration of lumacaftor and ivacaftor as a causal therapeutic approach].
Desch M
Med Monatsschr Pharm; 2016 Jan; 39(1):42-4. PubMed ID: 26975180
[No Abstract] [Full Text] [Related]
51. Cis variants identified in F508del complex alleles modulate CFTR channel rescue by small molecules.
Baatallah N; Bitam S; Martin N; Servel N; Costes B; Mekki C; Chevalier B; Pranke I; Simonin J; Girodon E; Hoffmann B; Mornon JP; Callebaut I; Sermet-Gaudelus I; Fanen P; Edelman A; Hinzpeter A
Hum Mutat; 2018 Apr; 39(4):506-514. PubMed ID: 29271547
[TBL] [Abstract][Full Text] [Related]
52. Excitement mounts for first disease-modifying cystic fibrosis drugs.
Opar A
Nat Rev Drug Discov; 2011 Jul; 10(7):479-80. PubMed ID: 21720393
[No Abstract] [Full Text] [Related]
53. Precision Medicine: At What Price?
Ferkol T; Quinton P
Am J Respir Crit Care Med; 2015 Sep; 192(6):658-9. PubMed ID: 26207804
[No Abstract] [Full Text] [Related]
54. The CF Canada-Sick Kids Program in individual CF therapy: A resource for the advancement of personalized medicine in CF.
Eckford PDW; McCormack J; Munsie L; He G; Stanojevic S; Pereira SL; Ho K; Avolio J; Bartlett C; Yang JY; Wong AP; Wellhauser L; Huan LJ; Jiang JX; Ouyang H; Du K; Klingel M; Kyriakopoulou L; Gonska T; Moraes TJ; Strug LJ; Rossant J; Ratjen F; Bear CE
J Cyst Fibros; 2019 Jan; 18(1):35-43. PubMed ID: 29685812
[TBL] [Abstract][Full Text] [Related]
55. Combined effects of VX-770 and VX-809 on several functional abnormalities of F508del-CFTR channels.
Kopeikin Z; Yuksek Z; Yang HY; Bompadre SG
J Cyst Fibros; 2014 Sep; 13(5):508-14. PubMed ID: 24796242
[TBL] [Abstract][Full Text] [Related]
56. Modifying disease in cystic fibrosis: current and future therapies on the horizon.
Ong T; Ramsey BW
Curr Opin Pulm Med; 2013 Nov; 19(6):645-51. PubMed ID: 24048086
[TBL] [Abstract][Full Text] [Related]
57. Cystic fibrosis in the era of genomic medicine.
Milla CE
Curr Opin Pediatr; 2013 Jun; 25(3):323-8. PubMed ID: 23652683
[TBL] [Abstract][Full Text] [Related]
58. Drug combination that corrects deficient protein in cystic fibrosis improves lung function.
Mayor S
BMJ; 2015 May; 350():h2689. PubMed ID: 25990552
[No Abstract] [Full Text] [Related]
59. Cystic Fibrosis-Associated Liver Disease in Lung Transplant Recipients.
Mallea J; Bolan C; Cortese C; Harnois D
Liver Transpl; 2019 Aug; 25(8):1265-1275. PubMed ID: 31102574
[TBL] [Abstract][Full Text] [Related]
60. Targeting the basic defect in cystic fibrosis.
Welsh MJ
N Engl J Med; 2010 Nov; 363(21):2056-7. PubMed ID: 21083391
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
